NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis → This Weight Loss Company Can't Make Enough Product (From Behind the Markets) (Ad) Free TVGN Stock Alerts $0.87 +0.04 (+4.82%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.82▼$0.8950-Day Range$0.77▼$2.4752-Week Range$0.75▼$21.09Volume233,438 shsAverage Volume631,384 shsMarket Capitalization$144.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Tevogen Bio alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Tevogen Bio Stock (NASDAQ:TVGN)Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.Read More TVGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVGN Stock News HeadlinesJune 12, 2024 | globenewswire.comTevogen Bio Set to Join Russell 3000® IndexJune 11, 2024 | globenewswire.comTevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development EffortsJune 7, 2024 | globenewswire.comCORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement EventJune 6, 2024 | globenewswire.comTevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement EventJune 6, 2024 | globenewswire.comTevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2May 30, 2024 | investorplace.comTVGN Stock Earnings: Tevogen Bio Holdings Reported Results for Q1 2024May 29, 2024 | finanznachrichten.deTevogen Bio Inc: Tevogen Bio Reports First Quarter 2024 Financial ResultsMay 29, 2024 | globenewswire.comTevogen Bio Reports First Quarter 2024 Financial ResultsMay 17, 2024 | finanznachrichten.deTevogen Bio Inc: Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic InitiativesMay 16, 2024 | globenewswire.comTevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic InitiativesMay 13, 2024 | msn.comWhy Is Tevogen Bio (TVGN) Stock Up 54% Today?May 13, 2024 | investorplace.comWhy Is Tevogen Bio (TVGN) Stock Up 54% Today?May 11, 2024 | finanznachrichten.deTevogen Bio Inc: Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational ObjectivesMay 10, 2024 | globenewswire.comTevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational ObjectivesMay 1, 2024 | globenewswire.comTevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational ObjectivesApril 27, 2024 | finanznachrichten.deTevogen Bio Inc: Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership AppointmentsApril 26, 2024 | globenewswire.comTevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership AppointmentsApril 26, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.98%April 20, 2024 | morningstar.comTevogen Bio Holdings Inc TVGNApril 16, 2024 | msn.comLive Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionApril 11, 2024 | finance.yahoo.comTevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target CancersApril 11, 2024 | globenewswire.comTevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target CancersApril 5, 2024 | seekingalpha.comTVGN Tevogen Bio Holdings Inc.April 4, 2024 | investorplace.comWhy Is Tevogen Bio (TVGN) Stock Up 46% Today?April 3, 2024 | globenewswire.comTevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate DevelopmentSee More Headlines Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CUSIPN/A CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-273.73% Return on Assets229.30% Debt Debt-to-Equity RatioN/A Current Ratio0.27 Quick Ratio0.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-0.79Miscellaneous Outstanding Shares166,114,000Free Float72,093,000Market Cap$144.52 million OptionableN/A Beta0.41 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Ryan H. Saadi M.D. (Age 59)M.P.H, M.P.H., Co-Founder, CEO & Chairman Comp: $501kMr. Kirti Desai (Age 67)Chief Financial Officer Comp: $300kDr. Neal Flomenberg M.D. (Age 70)Chief Scientific Officer and Global R&D Lead Comp: $350kMr. Sadiq Khan (Age 62)Chief Commercial Officer Key CompetitorsCabaletta BioNASDAQ:CABAReplimune GroupNASDAQ:REPLValnevaNASDAQ:VALNAllogene TherapeuticsNASDAQ:ALLOVoyager TherapeuticsNASDAQ:VYGRView All CompetitorsInsiders & InstitutionsKirti DesaiBought 3,000 shares on 6/12/2024Total: $2,460.00 ($0.82/share)Portland Global Advisors LLCBought 5,782,209 shares on 5/9/2024Ownership: 36.550%View All Insider TransactionsView All Institutional Transactions TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed in 2024? Tevogen Bio's stock was trading at $9.51 at the beginning of 2024. Since then, TVGN stock has decreased by 90.9% and is now trading at $0.87. View the best growth stocks for 2024 here. Who are Tevogen Bio's major shareholders? Tevogen Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Portland Global Advisors LLC (36.55%). View institutional ownership trends. How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVGN) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.